on Integrated BioPharma, Inc. (NASDAQ:INBP)
Integrated BioPharma Reports Financial Results for Q3 2025
Integrated BioPharma, Inc. (OTCQX:INBP) announced its financial results for the quarter ending September 30, 2025. The company reported a revenue of $12.7 million, a decrease of $0.9 million or roughly 6.6% compared to the same period in 2024.
Operating income also saw a decline, with $0.2 million recorded in Q3 2025, compared to $0.5 million the previous year. Net income for the quarter was approximately $0.1 million, or $0.00 per share, down from $0.3 million, or $0.01 per share in 2024.
The drop in revenue was partially attributed to the performance of the company's Contract Manufacturing Segment, where revenue from its two largest customers constituted 87% of total earnings in Q3 2025, up slightly from 85% in 2024.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Integrated BioPharma, Inc. news